Literature DB >> 28179039

Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis.

E Foglia1, T Schoeler1, E Klamerus1, K Morgan2, S Bhattacharyya1.   

Abstract

BACKGROUND: Substance use may increase the risk of non-adherence to antipsychotics, resulting in negative outcomes in patients with psychosis.
METHOD: We aimed to quantitatively summarize evidence regarding the effect of cannabis use, the most commonly used illicit drug amongst those with psychosis, on adherence to antipsychotic medication. Studies were identified through a systematic database search. Adopting random-effects models, pooled odds ratios (OR) for risk of non-adherence to antipsychotic medications were calculated comparing: cannabis-users at baseline v. non-users at baseline; non users v. continued cannabis users at follow-up; non-users v. former users at follow-up; former users v. current users.
RESULTS: Fifteen observational studies (n = 3678) were included. Increased risk of non-adherence was observed for cannabis users compared to non-users (OR 2.46, n = 3055). At follow-up, increased risk of non-adherence was observed for current users compared to non-users (OR 5.79, n = 175) and former users (OR 5.5, n = 192), while there was no difference between former users and non-users (OR 1.12, n = 187).
CONCLUSIONS: Cannabis use increases the risk of non-adherence and quitting cannabis use may help adherence to antipsychotics. Thus, cannabis use may represent a potential target for intervention to improve medication adherence in those with psychosis.

Entities:  

Keywords:  Antipsychotic; cannabis use; medication adherence; psychosis

Mesh:

Substances:

Year:  2017        PMID: 28179039     DOI: 10.1017/S0033291717000046

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  9 in total

Review 1.  Cannabis Use Among Patients With Psychotic Disorders.

Authors:  Matthew E Hirschtritt; Kelly C Young-Wolff; Daniel H Mathalon; Derek D Satre
Journal:  Perm J       Date:  2021-05-12

2.  Cognitive Behavioral Therapy Program for Cannabis Use Cessation in First-Episode Psychosis Patients: A 1-Year Randomized Controlled Trial.

Authors:  Itxaso González-Ortega; Enrique Echeburúa; Susana Alberich; Miguel Bernardo; Eduard Vieta; Gonzalo Salazar de Pablo; Ana González-Pinto
Journal:  Int J Environ Res Public Health       Date:  2022-06-15       Impact factor: 4.614

3.  Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis.

Authors:  Tabea Schoeler; Natalia Petros; Marta Di Forti; Ewa Klamerus; Enrico Foglia; Robin Murray; Sagnik Bhattacharyya
Journal:  Lancet Psychiatry       Date:  2017-07-10       Impact factor: 27.083

Review 4.  Therapeutic potential of medicinal marijuana: an educational primer for health care professionals.

Authors:  Yara Mouhamed; Andrey Vishnyakov; Bessi Qorri; Manpreet Sambi; Sm Signy Frank; Catherine Nowierski; Anmol Lamba; Umrao Bhatti; Myron R Szewczuk
Journal:  Drug Healthc Patient Saf       Date:  2018-06-11

5.  Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.

Authors:  Musa Basseer Sami; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2018-03-29       Impact factor: 4.153

6.  Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study.

Authors:  Nestor Szerman; Ignacio Basurte-Villamor; Pablo Vega; Jose Martinez-Raga; Carlos Parro-Torres; Julia Cambra Almerge; Lara Grau-López; Mario De Matteis; Francisco Arias
Journal:  Drugs Real World Outcomes       Date:  2020-03

7.  Determining factors for Cannabis use among Moroccans Schizophrenic Patients: A cross sectional study.

Authors:  Sara Bouri; Hanane Hanane; Khadija El Ayoubi Idrissi; Mohamed Amine Berraho; Abdelfattah Abdellaoui; Lyoussi Badiaa; Ismail Rammouz; Sanae Achour
Journal:  Avicenna J Phytomed       Date:  2020 Jan-Feb

8.  Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis.

Authors:  Priyanthi B Gjerde; Synne W Steen; Trude S J Vedal; Nils Eiel Steen; Elina J Reponen; Ole A Andreassen; Vidar M Steen; Ingrid Melle
Journal:  Front Psychiatry       Date:  2022-03-29       Impact factor: 4.157

9.  Risperidone Provides Better Improvement of Sleep Disturbances Than Haloperidol Therapy in Schizophrenia Patients With Cannabis-Positive Urinalysis.

Authors:  Peta-Gaye L Thomas-Brown; Jacqueline S Martin; Clayton A Sewell; Wendel D Abel; Maxine D Gossell-Williams
Journal:  Front Pharmacol       Date:  2018-07-18       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.